Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis by Singh, Swaroop S. et al.
Comparison of ACINUS, Caspase-3, and TUNEL as Apoptotic 
Markers in Determination of Tumor Growth Rates of Clinically 
Localized Prostate Cancer Using Image Analysis
Swaroop S. Singh#1,*, Diana C. Mehedint#2, O. Harris Ford III2, D. Antony Jeyaraj2, Elena A. 
Pop2, Susan J. Maygarden3, Anastasia Ivanova2,4, Rameela Chandrasekhar5,6, Gregory E. 
Wilding5,6, and James L. Mohler1,2,7,8
1Department of Urology, Roswell Park Cancer Institute, Buffalo, New York
2Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, 
Chapel Hill, North Carolina
3Department of Pathology and Laboratory Medicine, The University of North Carolina at Chapel 
Hill, Chapel Hill, North Carolina
4Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina
5Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, New York
6Department of Biostatistics, State University of New York, Buffalo, New York
7Department of Surgery, The University of North Carolina at Chapel Hill, Chapel Hill, North 
Carolina
8Department of Urology, State University of New York, Buffalo, New York
# These authors contributed equally to this work.
Abstract
BACKGROUND—The balance between apoptotic and proliferative processes determines the 
enlargement of a tumor. Accurate measurement of apoptotic and proliferative rates from 
diagnostic prostate biopsies would allow calculation of tumor growth rates in a population-based 
prostate cancer (CaP) study. Automated image analysis may be used if proliferation and apoptotic 
biomarkers provide clearly resolved immunostained images.
METHODS—Clinical CaP aggressiveness was assigned as low, intermediate or high using 
clinical criteria for 46 research subjects with newly diagnosed CaP. Diagnostic biopsy sections 
from the research subjects were dual-labeled for proliferation biomarker, Ki-67 and apoptotic 
biomarker, apoptotic chromatin condensation inducer in the nucleus (ACINUS). Apoptotic 
biomarkers, caspase-3 and terminal deoxyribonucleotidyltransferase mediated dUTP-biotin nick 
end labeling (TUNEL) were labeled separately. Images from immunostained sections were 
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analyzed using automated image analysis and tumor growth rates computed. Association between 
clinical CaP aggressiveness and tumor growth rates was explored.
RESULTS—Sixteen subjects had high, 17 had intermediate, and 13 had low clinical CaP 
aggressiveness. Positive immunostaining was localized to the nucleus for Ki-67, ACINUS, and 
TUNEL. A statistically significant linear trend across clinical CaP aggressiveness categories was 
found when tumor growth rates were calculated using ACINUS (P = 0.046). Logistic regression 
and ROC plots generated showed ACINUS (AUC = 0.677, P = 0.048) and caspase-3 (AUC = 
0.694, P = 0.038) to be better predictors than TUNEL (AUC = 0.669, P = 0.110).
CONCLUSIONS—ACINUS met the criteria for automated image analysis and for calculation of 
apoptotic rate. Tumor growth rates determined using automated image analysis should be 
evaluated for clinical prediction of CaP aggressiveness, treatment response, recurrence, and 
mortality.
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INTRODUCTION
Apoptosis is a fundamental and complex biological process that enables an organism to kill 
and remove unwanted cells during development, normal homeostasis and disease. This 
active, inherently programmed phenomenon is characterized by nuclear chromatin 
condensation and oligonucleosomal DNA fragmentation. Apoptosis has been shown to be 
initiated (or inhibited) by a variety of environmental stimuli, both physiological and 
pathological, and occurs spontaneously in untreated malignant neoplasms and some types of 
treatment-induced tumor regression [1].
Spontaneous continuous cell death is an inherent property of malignant neoplasms. 
Apoptotic and proliferative bodies have been found in large numbers in rapidly growing 
tumors. The balance between these two processes determines the rate of tumor growth [1]. 
During 3–7 months of neoadjuvant androgen deprivation therapy (ADT), reduction in 
prostate cancer (CaP) volume was accompanied by an increase in apoptotic index (AI), the 
percentage of apoptotic cells in a sample [2]. An increase in apoptotic activity and a 
decrease in proliferative activity were found after castration in the LuCaP 23.1 human CaP 
xenograft model. CaP recurrence during castration was associated with decreased AI but 
proliferative activity did not increase [3]. A statistically significant correlation also was 
found between AI and pathological stage (P < 0.001) and Gleason grade (P < 0.001). AI 
independently predicted progression-free probability in men, who underwent radical 
prostatectomy without adjuvant therapy [4].
CaP remains the most common malignancy and second leading cause of cancer deaths 
among men in the United States. African Americans experience a disproportionately high 
incidence and mortality from CaP compared to Caucasian Americans [5]. The North 
Carolina—Louisiana Prostate Cancer Project (PCaP) was developed as a multidisciplinary 
study to assess social, individual, and tumor-level causes of racial differences in CaP 
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mortality [6]. This population-based study includes incident CaP cases from more than 
1,000 African Americans and 1,000 Caucasian Americans. Tumor growth rate in men with 
newly diagnosed CaP will be evaluated to test whether it can be used to predict CaP 
recurrence and mortality.
Cellular proliferation and apoptotic rates must be measured accurately in CaP specimens to 
calculate tumor growth rate for an individual patient. Cellular proliferation can be 
determined using Ki-67 or proliferating cell nuclear antigen (PCNA). Both biomarkers are 
intra-nuclear proteins and therefore produce localized immunostaining appropriate for image 
analysis. Ki-67 is present during the active phases of the cell cycle (G1, S, G2, and mitosis), 
but PCNA is not cell-cycle specific [7]. Ki-67 labeling index (Ki-67 LI) has been used to 
predict CaP outcome in men after radical prostatectomy [8] and CaP-specific survival in 
patients managed by watchful waiting [9].
Apoptosis is less conspicuous histologically because it is completed swiftly, leaves no 
residua, and occurs in topographically scattered distribution [10]. The speed of apoptosis 
and rapidity of clearance of apoptotic bodies in vivo means that very few apoptotic bodies in 
a tissue section can represent a considerable degree of cumulative cell loss. Numerically 
small differences in AI are therefore of great biological importance [11].
Apoptosis is visualized commonly using terminal deoxyribonucleotidyltransferase (TdT) 
mediated dUTP-biotin nick end labeling (TUNEL) assay. DNA fragments in situ are 
detected using TdT to transfer biotin-dUTP to strand breaks of cleaved DNA, which are 
visualized using immunohistochemical stains [12]. Another method for detecting apoptosis 
uses the death protease, caspase-3. Caspases are crucial mediators of apoptosis. One major 
factor involved in the apoptotic oligonucleosomal fragmentation of nuclear DNA is caspase 
activated DNase (CAD), which in healthy cells exists as a dimer bound to its inhibitor, 
ICAD. During apoptosis ICAD is cleaved by active caspase-3 leading to release and 
activation of CAD. Activated CAD cleaves nuclear DNA at the boundaries between 
nucleosomes and produces oligonucleosomal DNA laddering [13]. Another target protein of 
caspases during apoptosis is apoptotic chromatin condensation inducer in the nucleus 
(ACINUS). ACINUS induces chromatin condensation without DNA fragmentation. During 
apoptosis, ACINUS is cleaved by caspase-3 and an unknown protease to produce a 23-kDa 
fragment (p23). ACINUS-p23 was found to mediate apoptotic chromatin condensation prior 
to DNA fragmentation in an in vitro system using permeabilized cells [10]. The expression 
of caspase-3 and ACINUS in CaP tissue sections can be visualized using immunohisto-
chemical stains.
Morphological characterization by microscopy remains the gold standard for accurate 
identification of apoptotic and proliferating cells. However, such quantitative measurements 
are time-consuming and lack objectivity and reproducibility, which makes identification of 
small changes in large populations difficult. Determination of apoptotic and proliferating 
indices requires visual examination of 1,000–10,000 cells to identify apoptotic and 
proliferating cells [14]. For example, commercial software (IDEAS®) and a multispectral 
imaging flow cytometer system was used to detect immunochemically labeled apoptotic 
cells from large numbers of images of colorectal cancer cell lines [14]. We developed Java-
Singh et al. Page 3













based software for automated quantitative nuclear analysis of images from immunostained 
formalin-fixed, paraffin-embedded prostate tissue sections [15]. This software has 
characterized successfully the expression of nuclear proteins androgen receptor (AR), Ki-67, 
and thioredoxin reductase 1 (TrxR1). Development of an automated method for accurate 
tumor growth rate calculation in prostate tissue sections will allow clinical evaluation of 
tumor growth rate as a biomarker to predict clinical CaP aggressiveness and treatment 
response. The objective of this pilot study was to determine which apoptotic marker is best 
suited, using automated image analysis, to assess tumor growth rates of newly diagnosed 
CaP using diagnostic prostate biopsies from research subjects enrolled in PCaP.
MATERIALS AND METHODS
Tissue Sections
Paraffin blocks containing diagnostic prostate biopsy specimens from 46 research subjects 
were obtained from PCaP. These subjects had no prior treatment for CaP. Four sections of 5 
μm thickness were cut from each diagnostic block containing CaP and 1 block without CaP. 
One section of each block was stained with hematoxylin and eosin (H&E) and sent to a 
referee pathologist for confirmation of diagnosis and Gleason score. All areas of CaP were 
encircled. Sections from the first 19 research subjects were stained for each biomarker 
separately. One section from the remaining 26 subjects was dual stained with Ki-67 and 
ACINUS and the two adjacent sections were immunostained for TUNEL or caspase-3.
Immunohistochemistry
Ki-67 and ACINUS—Formalin-fixed, paraffin-embedded diagnostic prostate biopsy 
sections were deparaffinized, rehydrated through alcohol gradient and antigen-retrieved 
using Citra buffer (Biocare, Walnut Creek, CA) for 10 min at 120°C and 21 PSI. The cooled 
sections were incubated with serum block, blocked for endogenous peroxidase using 3% 
H2O2 for 5 min at 37°C and blocked with avidin biotin for 15 min at 37°C (Vector, 
Burlington, CA). Sections were incubated with anti-Ki-67 (MIB-1 clone, Dako, Carpinteria, 
CA) primary antibody at 1:50 for 2 hr at 37°C. The sections were amplified using a dextran 
polymer (EnVision Doublestain System, Dako) and visualized using diaminobenzidine 
(DAB, Dako). The sections were labeled for ACINUS, using anti-ACINUS primary 
antibody (ABCAM, Cambridge, MA) at 1:500 for 1 hr at 37°C, amplified using the dextran 
polymer (EnVision Doublestain System) and visualized using Fast Red (Dako). Sections 
were counterstained using hematoxylin and mounted using an aqueous mounting medium.
Caspase-3—Formalin-fixed, paraffin-embedded diagnostic prostate biopsy sections were 
antigen retrieved and serum blocked as described for Ki-67 and ACINUS. Sections were 
incubated with anti-caspase-3 (R&D Systems, Minneapolis, MN) diluted 1:500 for 2 hr at 
37°C. Sections processed without antibody were used as negative controls. Peroxidase-
labeled polymer and DAB were used to visualize labeled antibody. Sections were 
counterstained with hematoxylin, dehydrated with graded concentrations of ethanol and 
Citrisol V (Fisher Scientific, Pittsburgh, PA) and mounted.
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TUNEL assay—Immunoperoxidase detection using indirect TUNEL method was used to 
detect apoptosis (In Situ Apoptosis Detection Kit (Chemicon International, Temecula, CA)). 
Sections were deparaffinized, re-hydrated and washed in PBS. Sections were incubated at 
room temperature in 20 μg/ml proteinase-K for 15 min. After rinsing in distilled water, 
sections were incubated in 3% H2O2 for 10 min to block endogenous peroxidase activity. 
The sections were washed in PBS and TdT reaction enzyme was added for 15–20 min and 
quenched using stop/wash buffer. The sections were washed three times with PBS. Anti-
digoxigenin-peroxidase conjugate was added and sections were incubated in a humidified 
chamber for 30 min at room temperature. The sections were washed and visualized using 
DAB. Sections were counterstained with hematoxylin, dehydrated with ethanol and Citrisol 
V (Fisher Scientific) and mounted.
Image Analysis
The imaging system consisted of a Leica DMRA2 microscope (Leica Microsystems, Inc., 
Bannockburn, IL) with a motorized stage controller (Ludl Electronic Products Ltd, 
Hawthorne, NY) equipped with a Hamamatsu 3CCD digital camera (Hamamatsu 
Corporation, Bridgewater, NJ) and a FlashPoint 3D image grabber card (Integral 
Technologies, Indianapolis, IN) in a Pentium 4-based personal computer. Image Pro Plus 
software (Media Cybernetics, Bethesda, MD) was used to acquire images from areas that 
corresponded to the encircled CaP. Ten images of 24-bit color depth and spatial resolution 
of 640 × 480 pixels were acquired at 40× from each section and saved as uncompressed 
TIFF images. Stromal and necrotic areas and other artifacts were removed from the images. 
Java-based image analysis software was used to determine the number of stained nuclei in 
the secretary epithelium [15]. Areas with cytoplasmic immunostaining were assessed 
visually using Image Pro Plus software (MediaCybernetics). Due to the inability of the 
software to differentiate clearly between red- and brown-stained nuclei, Ki-67 and ACINUS 
immunostaining were also visually assessed. The total cell count was determined 
automatically.
Calculation of Tumor Growth Rate
The proliferative and apoptotic rates were calculated for each image as:
(1)
(2)
Tumor growth rate was computed as:
(3)
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Measures of tumor growth rates using three apoptotic biomarkers were dichotomized into 
categories around the median. Logistic regression of clinical CaP aggressiveness categories 
on the dichotomized tumor growth rate was performed using the PROC LOGISTIC in SAS 
software (SAS Institute, Inc., Cary, NC). Tests for linear trend across the ordinal clinical 
CaP aggressiveness categories were examined. Additionally, clinical CaP aggressiveness 
score was dichotomized into categories representing low versus intermediate or high 
aggressiveness and logistic regression was then used to model the probability of 
intermediate/high aggressiveness as a function of the individual biomarkers.
In order to assess the predictive ability of the individual biomarkers, the receiver operating 
characteristic (ROC) curves for each biomarker were generated using tumor growth rates as 
predictors for clinical CaP aggressiveness. The area under each curve (AUC) was computed 
and compared using the nonparametric approach [16]. A nominal significance level of 0.05 
was used in all testing.
RESULTS
Prostate cancer of 46 PCaP research subjects was classified as high, intermediate or low 
clinical CaP aggressiveness using clinical criteria [6] (Table I). Sixteen research subjects had 
high, 17 had intermediate, and 13 had low clinical CaP aggressiveness (Table II).
Immunostaining for apoptosis with TUNEL and ACINUS produced clearly resolved images. 
Positive immunostaining with caspase-3 was found in the nucleus and cytoplasm whereas 
ACINUS and TUNEL immunostaining was localized to the nucleus (Fig. 1). Proliferation 
marker, Ki-67 produced immunostaining localized to the nucleus. The distribution of tumor 
growth rates categorized by clinical CaP aggressiveness showed greater overlap of low and 
high tumor growth rates for caspase-3 and TUNEL compared to ACINUS (Fig. 2).
Binomial regression of clinical CaP aggressiveness categories (low, intermediate, high) on 
dichotomized tumor growth rate using ACINUS (10 < Median ≤ 6), caspase-3 (11 < Median 
≤ 5) and TUNEL (11 < Median ≤ 5) biomarkers provided good discrimination among 
research subjects with low clinical CaP aggressiveness (Table III). ACINUS also provided 
good discrimination at high clinical CaP aggressiveness (3 < Median ≤ 10). The 
discrimination of research subjects by each biomarker is illustrated in Figure 3. A 
statistically significant linear trend was found when tumor growth rate was calculated across 
clinical CaP aggressiveness categories using ACINUS (P = 0.046). When examining the 
biomarkers individually, results from logistic regression and ROC plots (Fig. 4) indicated 
ACINUS (AUC = 0.677, P = 0.048) and capase-3 (AUC = 0.694, P = 0.038) had better 
predictive power for apoptosis than TUNEL (AUC = 0.669, P = 0.110). The AUC 
corresponding to each biomarker did not differ significantly from one another (P = 0.965).
DISCUSSION
Solid tumor growth reflects a balance between cell proliferation and cell death. Tumor 
growth results from the imbalance of cell gain and cell loss, and quantitative data indicate 
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that decreases from cell loss may be the main contributor to tumor growth [17]. Modeling 
tumor progression using data gathered from individual tumors may also assist in drug 
development by providing intermediate endpoints [18]. A high ratio of apoptosis to 
proliferation was found to correlate with improved survival and better prognosis in patients 
with cervical adenocarcinoma [19] and colorectal cancer [20], while a lower ratio was 
predictive of shorter survival in patients with glioblastoma multi-forme [21]. A better 
understanding of the growth rate of CaP is important not only for evaluating the necessity 
and type of treatment, but also for determining suitable follow-up intervals.
Apoptosis is important even when present at low frequency in vivo because of its short 
duration. The technique adopted to quantify apoptosis must be evaluated in the appropriate 
system being studied. Immunohistochemistry facilitates ready identification of protein 
biomarkers for rapid, reproducible and accurate assessment of proliferation and apoptosis. In 
the TUNEL assay, labeling of DNA strands by biotinylated nucleotides and subsequent 
immunodetection is used to identify cells with strand breakage. However, apoptosis is not 
the only situation in which sufficient DNA strand breaks occur. For example, necrosis, 
autolysis and DNA strand breaks that will be repaired subsequently label positively for 
TUNEL. Under some situations, apoptosis may not result in generation of nucleosomal 
fragments but in much larger fragments with presumably fewer detectable breaks [22].
Immunostaining for caspase-3 produced nonspecific positive immunostaining. Cytoplasmic 
stains are difficult to quantify using automated image analysis due the absence of clearly 
defined cellular boundaries. TUNEL and ACINUS immunostaining produced well resolved 
images suitable for computer-assisted image analysis. Distribution plots (box plots, Fig. 2) 
showed that ACINUS showed a marked difference in the distribution of tumor growth rates 
at low clinical CaP aggressiveness compared to high aggressiveness. Statistical analysis 
using binomial regression of clinical CaP aggressiveness on dichotomized tumor growth 
rates and AUCs from logistic regression models confirm tumor growth rates using ACINUS 
better predict clinical CaP aggressiveness compared to TUNEL. The immunostained images 
using ACINUS were localized in the nucleus, since the active form for ACINUS is located 
exclusively in the nucleus.
Java-based software [15] uses color components (hue, saturation, and intensity) of nuclear 
objects to differentiate immunopositive nuclei from the total population. However, due to 
the small difference in the levels of hue between the immunostain for Ki-67 (brown) and 
ACINUS (red), the software could not differentiate the two immunostains. This problem can 
be rectified by changing the protein used to visualize either of the two immunostains. The 
software successfully measured the total nuclear count and immuno-positive staining for 
TUNEL. In the course of the PCaP study, a large number of prostate biopsies will require 
analysis in order to compare tumor growth rates. Automated image analysis has been shown 
to quantify the number of nuclei stained in an image in a reliable and reproducible manner. 
Additional nuclear characteristics, such as mean optical density of nuclear stain and nuclear 
roundness, obtained from automated image analysis may be used in later studies.
In this study, ACINUS met the criteria for automated image analysis and for calculation of 
apoptotic rate. Tumor growth rate calculated using ACINUS was a better predictor of 
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clinical CaP aggressiveness than when calculated using TUNEL or caspase-3. Tumor 
growth rate will be evaluated ultimately as a biomarker to predict CaP aggressiveness, 
treatment response, recurrence and mortality. Data from the PCaP study will help uncover 
biological pathways relevant to CaP aggressiveness, inform the design of screening 
programs and community-based interventions and aid in development of methods to identify 
men at high risk of CaP mortality.
ACKNOWLEDGMENTS
PCaP is supported by the Department of Defense Prostate Cancer Research Program (DAMD 17-03-2-0052). The 
authors thank the staff, advisory committees and research subjects participating in the PCaP study for their 
significant contributions and Michael Ray, Roswell Park Cancer Institute, for assistance in preparing this 
manuscript. This study was supported by the NCI Cancer Center Support Grant to Roswell Park Cancer Institute 
(CA016156) and Lineberger Comprehensive Cancer Center (CA34026).
Grant sponsor: Department of Defense; Grant number: 17-03-2-0052; Grant sponsor: Roswell Park Cancer 
Institute; Grant number: CA016156; Grant sponsor: Lineberger Comprehensive Cancer Center; Grant number: 
CA34026.
REFERENCES
1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging 
implications in tissue kinetics. Br J Cancer. 1972; 26(4):239–257. [PubMed: 4561027] 
2. Miyata Y, Kanda S, Sakai H, Hakariya T, Kanetake H. Relationship between changes in prostate 
cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by 
neoadjuvant hormonal therapy and duration of such treatment. Urology. 2005; 65(6):1238–1243. 
[PubMed: 15922418] 
3. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD, Lange PH. Cell proliferation and apoptosis 
during prostatic tumor xeno-graft involution and regrowth after castration. Int J Cancer. 1996; 
67:785–790. [PubMed: 8824549] 
4. Dachille G, Cai T, Ludovico GM, Vestita G, Pagliarulo G, Nesi G, Mazzoli S, Meacci F, Mondaini 
N, Detti B, Bartoletti R. Prognostic role of cell apoptotic rate in prostate cancer: Outcome of a long-
time follow-up study. Oncol Rep. 2008; 19(2):541–545. [PubMed: 18202805] 
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin. 
2008; 58:71–96. [PubMed: 18287387] 
6. Schroeder JC, Bensen JT, Su LJ, Mishel M, Ivanova A, Smith GJ, Godley PA, Fontham ET, Mohler 
JL. The North Carolina-Louisiana Prostate Cancer Project (PCaP): Methods and design of a 
multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. 
Prostate. 2006; 66(11):1162–1176. [PubMed: 16676364] 
7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell 
proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J 
Immunol. 1984; 133:1710–1715. [PubMed: 6206131] 
8. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is 
a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996; 156(3):
1064–1068. [PubMed: 8709308] 
9. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity 
on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol. 1997; 157(1):
219–222. [PubMed: 8976256] 
10. Sahara S, Aoto M, Eguchi Y, Imamoto N, Yoneda Y, Tsujimoto Y. ACINUS is a caspase-3-
activated protein required for apoptotic chromatin condensation. Nature. 1999; 401(6749):168–
173. [PubMed: 10490026] 
11. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death in health and disease: The 
biology and regulation of apoptosis. Semin Cancer Biol. 1995; 6(1):3–16. [PubMed: 7548839] 
Singh et al. Page 8













12. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via 
specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992; 119(3):493–501. [PubMed: 
1400587] 
13. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase 
that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998; 391(6662):43–50. 
[PubMed: 9422506] 
14. Henery S, George T, Hall B, Basiji D, Ortyn W, Morrissey P. Quantitative image based apoptotic 
index measurement using multispectral imaging flow cytometry: A comparison with standard 
photometric methods. Apoptosis. 2008; 13(8):1054–1063. [PubMed: 18543109] 
15. Singh SS, Kim D, Mohler JL. Java Web Start based software for automated quantitative nuclear 
analysis of prostate cancer and benign prostate hyperplasia. Biomed Eng Online. 2005; 4:31. 
[PubMed: 15888205] 
16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated 
receiver operating character istic curves: A nonparametric approach. Biometrics. 1988; 44(3):837–
845. [PubMed: 3203132] 
17. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines 
net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol. 
1994; 144(5):1045–1057. [PubMed: 8178928] 
18. Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T. Tumor growth 
rates derived from data for patients in a clinical trial correlate strongly with patient survival: A 
novel strategy for evaluation of clinical trial data. Oncologist. 2008; 13(10):1046–1054. [PubMed: 
18838440] 
19. Sheridan MT, Cooper RA, West CM. A high ratio of apoptosis to proliferation correlates with 
improved survival after radiotherapy for cervical adenocarcinoma. Int J Radiat Oncol Biol Phys. 
1999; 44:507–512. [PubMed: 10348278] 
20. Koike M. Significance of spontaneous apoptosis during color-ectal tumorigenesis. J Surg Oncol. 
1996; 62(2):97–108. [PubMed: 8649048] 
21. Kuriyama H, Lamborn KR, O’Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, 
Buckner JC, Kuriyama N, Jenkins RB, Israel MA. Prognostic significance of an apoptotic index 
and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro Oncol. 2002; 
4(3):179–186. [PubMed: 12084348] 
22. Harrison DJ. Counting apoptosis—Why and how? J Clin Path Mol Pathol. 1996; 49:M245–M246.
Singh et al. Page 9














A: Ki-67 (brown) and ACINUS (red), (B) caspase-3 (brown), and (C) TUNEL (brown) 
immunostained images.
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Distribution of tumor growth rate measurements using 3 apoptotic biomarkers in 46 research 
subjects categorized by clinical CaP aggressiveness.
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Number of research subjects with low, intermediate and high clinical CaP aggressiveness 
and tumor growth rates above or below the median.
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ROC curves generated using tumor growth rates from ACINUS, caspase-3 and TUNEL as 
predictors of clinical CaP aggressiveness.
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TABLE I




Low Gleason sum < 7 and
Clinical stage T1–T2 and
PSA < 10
High Gleason sum ≥ 8 or
PSA > 20 or
Gleason sum = 7 and
Clinical stage T3–T4
Intermediate All other research subjects
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TABLE II
Clinical Characteristics of 46 Research Subjects
Clinical characteristics Number ofresearch subjects
Race
 African American 23
 Caucasian American 23
Serum PSA level
 <10 33
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TABLE III
Research Subjects Categorized Into Low, Intermediate and High Clinical CaP Aggressiveness and 















 <Median 10 10 3 0.046
 ≥Median 6 7 10
Caspase-3
 <Median 11 6 6 0.197
 ≥Median 5 11 7
TUNEL
 <Median 11 7 5 0.099
 ≥Median 5 10 8
P-value indicate calculated trend at 95% confidence interval.
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